SABRILEX 500 mg Oral Solution Granules
Cómo usar SABRILEX 500 mg ORAL SOLUTION GRANULES
Traducción generada por IA
Este contenido ha sido traducido automáticamente y se ofrece solo con fines informativos. No sustituye la consulta con un profesional sanitario.
Ver originalContenido del prospecto
Introduction
Package Leaflet: Information for the User
Sabrilex 500 mg granules for oral solution
Vigabatrin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again. If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Sabrilex and what is it used for
- What you need to know before you take Sabrilex
- How to take Sabrilex
- Possible side effects
- Storage of Sabrilex
- Contents of the pack and other information
1. What is Sabrilex and what is it used for
Sabrilex is used to help control various forms of epilepsy.
It is used in combination with your current medication to treat "difficult to control" epilepsy. It will initially be prescribed by a specialist. Your response to treatment will be monitored.
It is also used to control infant spasms (West syndrome).
2. What you need to know before you take Sabrilex
Do not take Sabrilex
- If you are allergic to vigabatrin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor before starting to take Sabrilex if:
- you are breast-feeding
- you are pregnant or planning to become pregnant
- you have suffered from depression or any other psychiatric disorder in the past
- you have had kidney problems
- you have had eye problems.
Visual field loss (loss of vision from the edges of your field of vision) may occur during treatment with Sabrilex. You should discuss this possibility with your doctor before starting treatment with this medicine. This visual field loss can be severe, leading to tunnel vision or loss of vision, and irreversible, so it must be detected early. It cannot be ruled out that this visual field loss may worsen after treatment is stopped. It is essential that you inform your doctor immediately if you notice any change in your vision. Your doctor will perform a visual field test and a visual acuity test before you start taking Sabrilex and at regular intervals during treatment. Sabrilex may cause a decrease in vision due to eye problems such as retinal disorders, blurred vision, optic atrophy, or optic neuritis (see section 4). If your vision changes, consult an ophthalmologist. |
If you develop symptoms such as drowsiness, decreased consciousness and movement (stupor) or confusion, consult your doctor, who will decide whether to reduce the dose or stop treatment.
A small number of people being treated with antiepileptics such as vigabatrin have had thoughts of harming themselves or committing suicide. If you have these thoughts at any time, contact your doctor immediately.
Children
Movement disorders have been reported in children treated for infant spasms (West syndrome). If you observe unusual movement disorders in the child, consult your doctor, who will decide whether to consider changing treatment.
Taking Sabrilex with other medicines
Please inform your doctor if you are taking clonazepam, as concomitant use with Sabrilex may increase the risk of sedation.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Sabrilex should not be taken in combination with other medicines that may have adverse effects on the eyes.
Pregnancy, breast-feeding, and fertility
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medicine. Do not take Sabrilex during pregnancy unless your doctor tells you to. Sabrilex may harm the fetus.
However, do not stop treatment abruptly, as this may endanger the health of the mother and the baby.
Sabrilex passes into breast milk. If you are breast-feeding, ask your doctor before using this medicine. You should not breast-feed during treatment.
Driving and using machines
Do not drive or operate machinery if your epilepsy is not controlled.
Sabrilex may sometimes cause symptoms such as drowsiness or dizziness, and your ability to concentrate and react may be impaired. If these symptoms occur during your treatment with Sabrilex, you should not perform any hazardous tasks such as driving or operating machinery.
Visual disturbances, which can affect your ability to drive or operate machinery, have occurred in some patients taking this medicine. If you want to continue driving, you should be examined regularly (every six months) to rule out visual disturbances, even if you do not notice any changes in your vision.
3. How to take Sabrilex
Follow your doctor's instructions for taking this medicine exactly. If you are unsure, consult your doctor again.
It is essential to follow your doctor's instructions exactly. Never change the dose.
Your doctor will prescribe the dose and adjust it individually for you.
Do not open the sachets until the time of taking your medicine. To take a dose, you should dissolve all the powder from the recommended number of sachets in half a glass of water or a soft drink such as fruit juice or milk. When all the powder has dissolved, drink the entire solution without leaving any. Sabrilex can be taken before or after meals.
The recommended starting dose is 1 g (2 sachets) per day. However, your doctor may increase or decrease the dose depending on your response to treatment; the usual daily dose for adults is 2 to 3 g (4 to 6 sachets). The maximum recommended dose is 3 g per day.
If you are an elderly patient and/or have kidney problems, your doctor will prescribe a lower dose.
Use in children
Resistant partial epilepsy
In children, the dose is based on age and weight. The recommended starting dose is 40 milligrams per kilogram of body weight per day. The following table shows the number of sachets to be administered to children depending on their body weight. Remember that this is only a guide. The child's doctor will decide whether to prescribe a slightly different dose.
Weight 10-15 kg 0.5-1 g (1-2 sachets)/day
15-30 kg 1-1.5 g (2-3 sachets)/day
30-50 kg 1.5-3 g (3-6 sachets)/day
More than 50 kg 2-3 g (4-6 sachets)/day (adult dose).
Infant spasms (West syndrome)
The recommended starting dose for infants with West syndrome (infant spasms) is 50 milligrams per kilogram of body weight per day, although sometimes higher doses may be administered.
Method of administration
The route of administration is oral (by mouth).
Always swallow the tablet with at least half a glass of water.
Sabrilex can be taken before or after meals.
The daily dose can be taken as a single dose or divided into two doses.
If you take more Sabrilex than you should
If you or your child accidentally take too many sachets of Sabrilex, consult your doctor immediately or go to the emergency department of the nearest hospital, accompanied by this leaflet.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Telephone 91 562 04 20.
Possible symptoms of overdose include drowsiness or loss/decreased level of consciousness.
If you forget to take Sabrilex
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, take only one dose. Do not take a double dose to make up for forgotten doses.
If you stop taking Sabrilex
Do not stop taking this medicine without consulting your doctor. If your doctor decides to stop your treatment, they will give you recommendations on how to gradually reduce the dose. Do not stop it abruptly, as this may cause your seizures to return.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
As with other antiepileptic medicines, some patients may experience an increase in the number of seizures (convulsions) while taking this medicine. If this happens to you or your child, contact your doctor immediately.
Tell your doctor immediately if you experience:
Very common side effects (may affect more than 1 in 10 people)
- Changes in the visual field - About 1/3 or 33% of patients treated with Sabrilex may have changes in the visual field (narrowing of the visual field). This "visual field defect" can range from mild to severe. These are usually detected after months or years of treatment with Sabrilex. Visual field changes can be irreversible, so they must be detected early. If you or your child experience any visual disturbances, contact your doctor or hospital immediately.
Other side effects include:
Very common side effects (may affect more than 1 in 10 people)
- Fatigue and increased drowsiness
- Joint pain.
Common side effects (may affect up to 1 in 10 people)
- Headache
- Weight gain
- Tremor
- Swelling (edema)
- Dizziness
- Feeling of numbness or tingling
- Concentration and memory disorders
- Psychological disorders, including agitation, aggression, nervousness, irritability, depression, thought disorders, and paranoid reaction (progressive mental disorder), insomnia. These side effects are generally reversible with dose reduction or gradual discontinuation of treatment. However, do not reduce your dose without consulting your doctor first. Contact your doctor if you experience these side effects.
- Nausea, vomiting, and abdominal pain
- Blurred vision, double vision, and rapid involuntary eye movements
- Speech disorders
- Decreased number of red blood cells (anemia)
- Unusual hair loss or weakened hair (alopecia).
Uncommon side effects (may affect up to 1 in 100 people)
- Lack of coordination, clumsiness
- More severe psychological disorders such as hypomania, mania, and psychosis
- Skin rash.
Rare side effects (may affect up to 1 in 1,000 people)
- Severe allergic reaction, which causes swelling of the face or throat. If you experience any of these symptoms, inform your doctor immediately.
- Hives
- Marked sedation, stupor, and confusion. These side effects are usually reversible with dose reduction or gradual discontinuation of treatment. However, do not reduce your dose without consulting your doctor first. Contact your doctor if you experience these side effects.
- Suicidal attempt
- Other eye disorders such as retinal disorders.
Very rare side effects (may affect up to 1 in 10,000 people)
- Other eye disorders such as optic neuritis and optic atrophy
- Hallucinations
- Liver disorders.
Side effects of unknown frequency (frequency cannot be estimated from the available data)
- Decreased visual acuity
- Abnormal changes in brain images taken by magnetic resonance imaging
- Swelling in the protective layer of nerve cells in part of the brain as seen in magnetic resonance images.
Other side effects in children
Very common side effects (may affect more than 1 in 10 people)
- Excitement or restlessness.
Side effects of unknown frequency (cannot be estimated from the available data)
- Movement disorders in children treated for infant spasms
- Abnormal changes in brain images taken by magnetic resonance imaging, particularly in infants
- Swelling in the protective layer of nerve cells in part of the brain as seen in magnetic resonance images.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Sabrilex
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and sachets. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicine to a pharmacy for disposal. If you are unsure, ask your pharmacist how to dispose of the containers and any unused medicine. This will help protect the environment.
6. Contents of the pack and other information
Composition of Sabrilex
- The active substance is vigabatrin. One sachet contains 500 mg of vigabatrin.
- The other ingredients are:
Povidone K30 (E1201).
Appearance and packaging
Sabrilex granules for oral solution are a white to off-white granular powder.
It is available in packs of 50, 60, or 100 sachets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder is:
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona
Spain
The manufacturer is:
Patheon France
Boulevard de Champaret
38300 Bourgoin-Jallieu (France)
Or
Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst-Brueningstrase 50
65926 Frankfurt am Main (Germany)
This medicine is authorised in the Member States of the European Economic Area under the following names:
Austria:Sabril 500 mg lösliches Pulver
Denmark:Sabrilex
Finland:Sabrilex 500 mg rakeet oraaliliuosta varten
France:Sabril 500 mg granulés pour solution buvable en sachet-dose
Germany:Sabril Beutel
Ireland:Sabril 500 mg granules for oral solution
Italy:Sabril 500 mg granulato per soluzione orale
Netherlands:Sabril 500 mg granulaat voor drank
Portugal:Sabril 500 mg granulado para solução oral
Spain:Sabrilex 500 mg granulado para solución oral
Sweden:Sabrilex 500 mg granulat till oral lösning
United Kingdom:Sabril 500 mg granules for oral solution
Date of last revision of this leaflet:January 2021
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
-
- País de registro
- Forma farmacéuticaORAL SOLUTION/SUSPENSION, 500 mg
- Código ATCN03AG04
- Precio medio en farmacia30.13 EUR
- Principio activo
- Requiere recetaSí
- Fabricante
- Esta información es de carácter general y no sustituye la consulta con un profesional sanitario.
- Alternativas a SABRILEX 500 mg ORAL SOLUTION GRANULESForma farmacéutica: TABLET, 100 mgPrincipio activo: vigabatrinFabricante: Orphelia PharmaRequiere recetaForma farmacéutica: TABLET, 500 mgPrincipio activo: vigabatrinFabricante: Orphelia PharmaRequiere recetaForma farmacéutica: TABLET, 500 mgPrincipio activo: vigabatrinFabricante: Sanofi Aventis S.A.Requiere receta
Médicos online para SABRILEX 500 mg ORAL SOLUTION GRANULES
Comenta la dosis, los posibles efectos secundarios, interacciones, contraindicaciones o la revisión de receta de SABRILEX 500 mg ORAL SOLUTION GRANULES, sujeto a valoración médica y a la normativa local.
Obtén una receta de SABRILEX 500 mg ORAL SOLUTION GRANULES online
Rellena un formulario de 2 minutos
Cuéntanos tus síntomas, historial y el medicamento que necesitas.
Elige un médico o nosotros te asignamos uno
Escoge un especialista o te conectamos con el próximo médico disponible.
El médico revisa tu caso
Normalmente en 30 minutos. Puede hacerte preguntas adicionales por chat.
Recógela en cualquier farmacia
Receta electrónica enviada a tu correo, válida en toda España.
Preguntas frecuentes
¿Se requiere receta para SABRILEX 500 mg ORAL SOLUTION GRANULES?
SABRILEX 500 mg ORAL SOLUTION GRANULES requires receta en Spain. Puedes confirmarlo con un médico online según tu caso.
¿Cuál es el principio activo de SABRILEX 500 mg ORAL SOLUTION GRANULES?
El principio activo de SABRILEX 500 mg ORAL SOLUTION GRANULES es vigabatrin. Esta información ayuda a identificar medicamentos con la misma composición pero con diferentes nombres comerciales.
¿Cuánto cuesta SABRILEX 500 mg ORAL SOLUTION GRANULES en farmacia?
El precio medio en farmacia de SABRILEX 500 mg ORAL SOLUTION GRANULES es de aproximadamente 30.13 EUR. Puede variar según el fabricante y la forma farmacéutica.
¿Quién fabrica SABRILEX 500 mg ORAL SOLUTION GRANULES?
SABRILEX 500 mg ORAL SOLUTION GRANULES es fabricado por Sanofi Aventis S.A.. La marca y el envase pueden variar según el distribuidor.
¿Qué médicos pueden recetar SABRILEX 500 mg ORAL SOLUTION GRANULES online?
Los Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists pueden valorar la prescripción de SABRILEX 500 mg ORAL SOLUTION GRANULES cuando esté clínicamente indicado. Puedes reservar una videoconsulta para comentar tu caso y las opciones de tratamiento.
¿Cómo comprar SABRILEX 500 mg ORAL SOLUTION GRANULES en España?
España cuenta con una infraestructura sanitaria bien desarrollada en ciudades principales como Madrid, Barcelona, Valencia y Sevilla. Las farmacias están ampliamente disponibles y operan bajo estrictas regulaciones, garantizando el acceso a medicamentos con receta.
Puedes comprar SABRILEX 500 mg ORAL SOLUTION GRANULES en Madrid, Barcelona, Sevilla o Valencia en cualquier farmacia local con una receta válida.
Para obtener una receta, puedes utilizar Oladoctor:
¿Cuáles son las alternativas a SABRILEX 500 mg ORAL SOLUTION GRANULES?
Otros medicamentos con el mismo principio activo (vigabatrin) incluyen KIGABEQ 100 mg SOLUBLE TABLETS, KIGABEQ 500 mg SOLUBLE TABLETS, SABRILEX 500 mg FILM-COATED TABLETS. Pueden tener diferentes nombres comerciales o formulaciones, pero contienen el mismo componente terapéutico. Consulta siempre con un médico antes de cambiar o iniciar un nuevo medicamento.
